{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Exagen, Inc. Hits New 52-Week High of $11.75, Up 479.9% Year-Over-Year
Exagen, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 11.75 on October 14, 2025, reflecting a substantial annual increase. Despite this performance, the company remains unprofitable, with a negative price-to-earnings ratio and a high price-to-book ratio, highlighting sector volatility.
Exagen, Inc. Hits New 52-Week High of $11.09, Surging 447%
Exagen, Inc. has achieved a new 52-week high of USD 11.09, reflecting a significant performance improvement over the past year with a gain of 447.24%. Despite its loss-making status, the company has a market capitalization of USD 216 million and faces challenges with negative return on equity and a high price-to-book ratio.
Exagen, Inc. Hits New 52-Week High of $10.83, Up 441.71%
Exagen, Inc. has achieved a new 52-week high, reflecting a significant increase in its stock performance over the past year. With a market capitalization of USD 216 million, the company faces challenges, including a negative return on equity and a high price-to-book ratio, as it competes in the biotechnology sector.
Is Exagen, Inc. technically bullish or bearish?
As of September 11, 2025, Exagen, Inc. shows a bullish technical trend despite mixed signals from the RSI and KST, having outperformed the S&P 500 with a year-to-date return of 135.37% compared to 12.22%.
Is Exagen, Inc. technically bullish or bearish?
As of May 8, 2024, the trend is mildly bearish with weak strength, indicated by a bullish MACD but a bearish RSI, while moving averages and Bollinger Bands show mixed signals, suggesting a cautious outlook despite some bullish indicators.
Who are in the management team of Exagen, Inc.?
As of March 2022, the management team of Exagen, Inc. includes Mr. Brian Birk (Independent Chairman), Mr. Fortunato Rocca (President and CEO), and several Independent Directors: Mr. Jeffrey Elliott, Ms. Wendy Johnson, Dr. Tina Nova, Dr. Ebetuel Pallares, and Dr. Bruce Robertson.
What does Exagen, Inc. do?
Exagen, Inc. is a life sciences company focused on diagnostic and prognostic testing for autoimmune conditions, with recent net sales of $15 million and a market cap of $168.94 million. As of March 2025, it reported a net profit of -$4 million.
How big is Exagen, Inc.?
As of Jun 18, Exagen, Inc. has a market capitalization of 168.94 million, with net sales of 56.72 million and a net profit of -15.51 million over the last four quarters. Shareholder's funds are 9.54 million, and total assets amount to 45.40 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
